The U.S. FDA defines whole grains as consisting of the intact, ground, cracked, or flaked fruit of the grains whose principal components, the starchy endosperm, germ, and bran, are present in the same relative proportions as they exist in the intact grain. We evaluated the effect of applying the FDA definition of whole grains to the strength of scientific evidence in support of claims for risk reduction of cardiovascular disease (CVD). We concluded that using the FDA definition for whole grains as a selection criterion is limiting, because the majority of existing studies often use a broader meaning to define whole grains. When considering only whole grain studies that met the FDA definition, we found insufficient scientific evidence to support a claim that whole grain intake reduces the risk of CVD. However, a whole grain and reduced risk of CVD health claim is supported when using a broader concept of whole grain to include studies that considered intake of fiber-rich bran and germ as well as whole grain. This type of analysis is complicated by diversity in nutrients and bioactive components among different types of whole grains.
Introduction
In the US, food laws and regulations are generally supported by sound scientific evidence and aim to promote health and wellbeing by providing the public with the basis to make informed nutritional choices. At times, food laws and regulations become asynchronous. Either new evidence is discovered that contradicts the previous scientific consensus or new policies are introduced that may have the unintended consequence of misdirecting the public from good nutritional choices. Thus, it is necessary to periodically review the scientific evidence and update public policy to provide optimal nutritional guidance.
U.S. whole grain health claim regulations
One means to disseminate nutritional information is through label claims, in particular health claims, for foods and dietary supplements. These claims are regulated by the U.S. FDA under the Federal Food, Drug and Cosmetic Act. Health claims for food labels are authorized in the US by 2 amendments to the Federal Food, Drug and Cosmetic Act: the Nutrition Labeling and Education Act (NLEA) 3 of 1990 and the Food and Drug Administration Modernization Act (FDAMA) of 1997. Under the NLEA, a health claim is a food label statement that characterizes a relationship between a food ingredient or specific food and a disease. Health claims must be authorized and published as regulations by the FDA to be used in food labels (1) . To be approved as an NLEA health claim, the FDA must evaluate the supporting evidence to ascertain it meets the standard of significant scientific agreement, a level that has been described as well after the state of emerging science but before unanimous agreement. Such claims are also known as unqualified health claims. In response to a series of court rulings, the FDA has exercised enforcement discretion to also allow claims based on a lesser standard of evidence if they contain language qualifying the strength of the claim. These are known as qualified health claims. FDAMA health claims are based on an 1 This review summarizes the findings of a recent Life Sciences Research Office (LSRO) report, "Whole Grain Intake and Cardiovascular Disease and Whole Grain Intake and Diabetes-A Review" (Bethesda, MD: Life Sciences Research Office, 2008). The supplement coordinator for this supplement is Michael C. Falk, LSRO. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The LSRO report was developed under a contract between the Kellogg Company and LSRO. An independent Expert Panel appointed by LSRO on the basis of their qualifications and freedom from conflict of interest provided scientific oversight and direction for the study. The Kellogg Company provided a limited review of the report to assure contractual conformance. A. Catharine Ross handled the manuscript review process, and had no conflict of interest. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition. 2 Author disclosures: F. F. De Moura, K. D. Lewis, and M. C. Falk, no conflicts of interest. * To whom all correspondence should be addressed. E-mail: falkm@LSRO.org. 3 Abbreviations used: AACC, American Association for Cereal Chemists; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; FDAMA, Food and Drug Administration Modernization Act; LDL-C, LDL cholesterol; LSRO, Life Sciences Research Office; MI, myocardial infarction; ND, not detected; NLEA, Nutrition Labeling and Education Act; SBP, systolic blood pressure; TC, total cholesterol. authoritative statement from an appropriate federal agency or the National Academy of Sciences (2) . Distributors or manufacturers may submit to FDA a notification of a FDAMA health claim and if FDA does not prohibit or modify it within 120 d of receipt of the notification, the claim may be used. Therefore, the health claim provisions in FDAMA were intended to expedite the process by which the use of food label health claims are authorized (3) .
Composition and definition of whole grains A whole cereal grain is the fruit (also known as the seed, caryopsis, or kernel) of plants belonging to the Poaceae (or Gramineae) family also known as grasses. Some examples of cereal grains are wheat, rice, barley, corn, rye, oats, millet, sorghum, teff, triticale, canary seed, Job's tears, fonio, and wild rice. The seed is composed of 3 parts: the endosperm; the bran, which is the outer layer of the whole grain; and the germ or embryo, which is located at the base of the grain. There is great variability among the various whole grains in their content of macronutrients, micronutrients, and bioactive components, including components thought to have a role in disease prevention such as fiber, folate, phenolic compounds, lignan, and sterols (Tables 1 and 2) .
Although working definitions of whole grains were in common use, it was not until 1999 that a standardized definition of whole grains was recommended on the basis of a consensus among an ad hoc committee of experts from the American Association for Cereal Chemists (AACC). In 2006, the AACC whole grains definition was adopted by the FDA in the document "Whole Grain Label Statements" (4) to provide guidance to the industry about what the agency considers to be whole grain and to assist manufacturers in labeling their products. The FDA defines whole grains as consisting of the "intact, ground, cracked or flaked fruit of the grains whose principal components-the starchy endosperm, germ and bran -are present in the same relative proportions as they exist in the intact grain." For purposes of this review, we will refer to the whole grains definition as the FDA definition of whole grains. The FDA has approved health claims relating to the effect of diet and reduction of risk of cardiovascular disease (CVD) (5). Three NLEA health claims have been approved for grain products (not whole grains), 1 related to cancer (6) and 2 related to coronary heart disease (CHD) (7, 8) . All health claims for grain products refer to a specific substance, 1 to total dietary fiber, the others to soluble dietary fiber, and a disease component. The FDAMA health claim addressing whole grains is based on the following authoritative statement: "diets high in plant foodsi.e., fruits, vegetables, legumes, and whole grain cereals-are associated with lower occurrence of CHD and cancers of the lung, colon, esophagus, and stomach" extracted from the NRC report (9) . The scientific research upon which these claims were based was largely conducted prior to the 2006 release of the FDA guidance document on the definition of whole grains. In this context, we conducted an independent review of the scientific literature to evaluate the effect of applying the FDA definition of whole grains on the strength of scientific evidence in support of whole-grain health claims for risk reduction of CVD and diabetes (10) . Here, we restrict the results and conclusions of that review regarding the outcomes for CVD only and expand beyond the report to elaborate public health implications. It is important to note that the FDA has not conducted such a review, because the only health claim petitions related to whole grains were submitted under FDAMA and based on the conclusions of the NRC rather than an independent FDA review of the literature.
Methodology

Literature search
We conducted a comprehensive search of the scientific literature by searching MEDLINE for articles published through February 2008. The following search strategy was used to identify relevant articles: (whole grain OR whole grains) AND (cardiovascular disease OR heart OR coronary heart disease OR stroke OR blood pressure OR myocardial infarction OR health OR diabetes). The MEDLINE searches returned 634 potentially relevant articles. Additional articles were identified from a Web of Science database search using the same keywords used for the MEDLINE search. Other studies were identified by bibliographic searches of relevant reviews and articles.
The Life Sciences Research Office (LSRO) report was guided by an independent expert panel composed of Julie Mares, Ph.D., Judith Marlett, Ph.D., Harry Sapirstein, Ph.D., and James Hoadley, Ph.D., whose fields of expertise are in epidemiology, nutrition, cereal chemistry, and federal food regulations, respectively. Two scientists independently reviewed each article for inclusion and to ensure the information was accurately abstracted from the article. Further details about methodology may be found in the LSRO report.
Inclusion criteria
The inclusion criteria were derived from the specifications of the FDA guidelines for studies eligible to establish a health claim under the NLEA (22) . Therefore, reviews, editorials, and metaanalysis studies (n = 200) were excluded, as were studies not written in English (n = 28). Although the FDA may use animal and in vitro studies as background information, only human intervention and observational studies were considered for the purpose of this study. According to the FDA, only these studies can provide evidence from which scientific conclusions can be drawn about substance and disease relationships in humans. Consequently, animal and in vitro studies were also excluded (n = 79). A total of 327 articles remained. After reading titles and abstracts, 204 articles were evaluated further. Studies were considered if they measured a validated endpoint [i.e. CHD, 
concentration] for CVD in a healthy U.S population and populations representative of the US. Two scientists independently reviewed each article for inclusion and to ensure the information was accurately abstracted from the article. LSRO first analyzed only studies that explicitly described or defined whole grains according to the FDA definition of whole grains to evaluate the effect of applying the FDA definition of whole grains on the strength of the scientific evidence. Later, LSRO expanded the analysis to include studies with a broader definition of whole grains, including studies that added bran and/or germ along with whole grains or studies that did not explicitly use the term whole grains but were in fact conducted with individual whole grains (e.g. oats or barley). Other sources of dietary fiber not derived from whole grains or typically found in whole grain foods (e.g. psyllium seed husk, inulin) were not included.
Results
Restricted analysis (FDA definition only) Only 4 studies conformed to the FDA definition of whole grains. Two were observational studies, including a prospective cohort study (23) and a cross-sectional study (24) . Jensen et al. (23) observed a reduced relative risk of CHD comparing the highest to the lowest quintile of whole grain intake (P-trend = 0.01). Jensen et al. (24) observed a decrease in total cholesterol of 0.16 mmol/L comparing the highest to the lowest quintile of whole grain intake (P-trend = 0.02). Two were randomized, crossover design intervention studies (25, 26) . Notably, both of these were published after the FDA definition of whole grains was publicly released. Neither study evaluated health outcomes per se but both evaluated surrogate endpoints such as TC, LDL-C, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Neither study observed any significant differences from control. Although the 2 observational studies observed a significant reduction of CVD-related surrogate endpoints, the absence of support from intervention studies leads to the conclusion that the evidence does not support a health claim for the reduced risk of CVD.
Expanded analysis
The expanded approach included additional human studies for a total of 29 (15 intervention and 14 observational) studies for the association between whole grain consumption and CVD.
Most of the observational studies in the expanded definition analysis (Table 3) were excluded from the FDA definition because they considered the intake of bran, germ, or fiber along with whole grain foods. Twelve additional observational studies were included in the evaluation when considering an expanded definition of whole grains. Of these 12 studies, 10 defined whole grains as described by Jacobs Jr. et al. (27) , who included individual bran and germ as whole grain: Esmaillzadeh et al. (36); 1 study assessed intake of whole grain bread (37, 38) ; and 1 study evaluated the effect of oats (39) . Results of all 14 observational studies included in the expanded definition, regardless of their whole grain source, suggested a protective association between whole grain intake and risk of CVD (Table 3) .
Most of the intervention studies in the expanded definition analysis (Table 4) were excluded from the FDA definition analysis because the authors had not explicitly stated that the endosperm, bran, and germ are present in the same proportion as required by the FDA definition. Although the intervention study by Andersson et al. (25) that met the FDA definition reported no effect on CVD outcomes, other intervention studies in the expanded definition generally reported a beneficial effect. A beneficial effect of oats was reported in 6 studies (40-45), whereas only 1 study showed no effect (46) . Studies of oats that reported a positive effect were conducted for 6-8 wk compared Whole grain intake and cardiovascular disease and whole grain intake and diabetes: a review 2223S
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jn.nutrition.org with fewer than 3 wk for those studies that reported no beneficial effect. Four intervention studies with barley showed a reduction in plasma TC and LDL-C levels. Three of these barley studies were published by the same research group in the US (47) (48) (49) and the other was conducted by a research group in Japan (50) . Two of these studies had a similar study design, sample size, and study duration. One studied a diverse population of American men with hypercholesterolemia (48) and the other studied healthy Japanese women (50), but they reported similar reductions in TC (20-15%) and LDL-C (21%) levels. The positive effect of barley reported across population, gender, and health status adds strength to the evidence for a beneficial health effect of barley on plasma TC and LDL-C levels. A consistent definition of whole grains has not been applied in existing research that investigates the health benefits of consuming whole grains. As such, drawing specific conclusions about health benefits of whole grains in general from the body of scientific literature is confounded, typically with bran/dietary fiber. Using the FDA definition for whole grains as a selection criterion is limiting, because the vast majority of studies often have used a broader meaning to categorize a grain product as whole grain. Restricting the analysis of the literature about health benefits of whole grains to studies explicitly using the FDA definition of whole grains results in the exclusion of the majority of observational studies, because they include the intake of bran and germ to evaluate the health effect of whole grains, and a great number of intervention studies that use individual grains, because they do not explicitly state that the endosperm, bran, and germ are present in the same proportion.
The scientific evidence on the relationship between whole grain consumption and CVD can be evaluated 2 ways (Table 5) . First, there is no consistent scientific evidence to support a whole grain and CVD risk health claim if only whole grain studies that explicitly conform to the FDA whole grain definition (using the "native" proportion of endosperm, bran, and germ) are considered. To date, only 4 studies conform to the FDA definition. In contrast, a whole grain and CVD health claim is supported using a broader concept of whole grain typically used in the scientific literature that includes whole grain foods containing principal components such as bran. A health claim for the relationship between soluble fiber from oats and barley and risk of CHD has been approved by the FDA (53) .
The results also suggest that the health benefits observed from consumption of 1 whole grain do not necessarily reflect the same benefit or the same magnitude of benefit from other whole grains. For example, intake of oat and barley products for 5-6 wk had a beneficial effect on reducing TC and LDL-C plasma levels, whereas intake of whole wheat products elicited no significant change in those variables when consumed for the same length of time (Table 4) . This may be due to the diversity among whole grains in terms of macronutrient, micronutrient, fiber, and bioactive components. For example, the total fiber content of bulgur and barley is~5-fold higher than that of brown rice (Table 1) . Rye contains the highest amount of lignan and sterols (other than phenolic acids and phenolic lipids) compared with wheat, oats, and barley (Table 2) . Furthermore, some nutrients are absent in some grains but present in high amounts in other grains as in the case of vitamin A, b-carotene, lutein, and zeaxanthin that are present in high levels in corn but absent in brown rice, oats, and sorghum (Table 1) . Therefore, the variation in constituents among types of whole grains should be considered when associating whole grains with a health benefit. Among the intervention studies included in the expanded definition, only the studies conducted with oats and barley (44, 48) reported reduced cholesterol levels. Milled wheat did not lower serum cholesterol levels (25) . Therefore, studying the association of individual grains, rather than an entire category of whole grains, with a particular health benefit would provide additional evidence about the possible beneficial components of whole grains.
Beyond the LSRO report: implications for public health Because the majority of scientific evidence supporting the CVD health benefits of whole grains is confounded, typically with bran, germ, or fiber, it is difficult to dissociate the effect of whole grains from that of their major components. Restricting the scientific evidence to only that which expressly and clearly addresses whole grains is an artificial construct and obscures the potential benefits of whole grain components. The scientific evidence supporting the CVD health benefits of fiber are well documented in approved health claims. Public health policy and dietary recommendations on carbohydrate intake should clearly communicate the value of whole grains, grain foods, and cereal fiber by broadening recommendations to any grain that is a good source of fiber. Moreover, because the FDA definition does not include an assessment of fiber, the label "whole grains" can be mistakenly understood as a good or excellent source of fiber, although that is not necessarily the case. This may have the negative effect of limiting fiber intake rather than increasing it. Broadening recommendations to include bran and including an assessment for fiber may be warranted to significantly increase Americans' fiber intake. Although whole grains share enough similarities to be thought of as a class, there are significant differences among the individual grains not only in the fiber content (Table 1) or bran but also in the content of putative bioactive compounds ( Table 2 ), such that products of the various grains may have substantially different health benefits. The majority of the intervention studies on whole grain and CVD were conducted with oats and barley (Table 3) . Potentially, claims of whole grain health benefits could be restricted to only those grains for which adequate scientific support can be demonstrated to avoid generalizing conclusions based on evidence developed on a specific grain. Additional research is required to identify the health benefits of whole grains other than oats and barley, and on the relative contribution to health benefit of the individual grain components such as bran, germ, fiber, and phytochemicals. 
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